HK1155163A1 - 羥基烷基 吡咯衍生物的阻轉異構體 - Google Patents

羥基烷基 吡咯衍生物的阻轉異構體

Info

Publication number
HK1155163A1
HK1155163A1 HK11109377.1A HK11109377A HK1155163A1 HK 1155163 A1 HK1155163 A1 HK 1155163A1 HK 11109377 A HK11109377 A HK 11109377A HK 1155163 A1 HK1155163 A1 HK 1155163A1
Authority
HK
Hong Kong
Prior art keywords
atropisomers
hydroxyalkyl
pyrrole derivatives
pyrrole
derivatives
Prior art date
Application number
HK11109377.1A
Other languages
English (en)
Inventor
Nuss John
Williams Matthew
Mohan Raju
Martin Richard
Wang Tie-Lin
Aoki Kazumasa
Tsuruoka Hiroyuki
Hayashi Noriyuki
Homma Tsuyoshi
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of HK1155163A1 publication Critical patent/HK1155163A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HK11109377.1A 2008-10-08 2011-09-05 羥基烷基 吡咯衍生物的阻轉異構體 HK1155163A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10371508P 2008-10-08 2008-10-08
PCT/US2009/059847 WO2010042622A1 (en) 2008-10-08 2009-10-07 Atropisomers of (hydroxyalkyl) pyrrole derivatives

Publications (1)

Publication Number Publication Date
HK1155163A1 true HK1155163A1 (zh) 2012-05-11

Family

ID=41360127

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11109377.1A HK1155163A1 (zh) 2008-10-08 2011-09-05 羥基烷基 吡咯衍生物的阻轉異構體

Country Status (13)

Country Link
US (1) US8487117B2 (zh)
EP (1) EP2349997B1 (zh)
JP (2) JP5767586B2 (zh)
KR (1) KR101643285B1 (zh)
CN (1) CN102186817B (zh)
AU (1) AU2009302371B2 (zh)
BR (1) BRPI0920459B1 (zh)
CA (1) CA2736923C (zh)
ES (1) ES2547697T3 (zh)
HK (1) HK1155163A1 (zh)
IL (1) IL212170A (zh)
TW (2) TWI593674B (zh)
WO (1) WO2010042622A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6422871B2 (ja) 2013-08-27 2018-11-14 第一三共株式会社 ピロール誘導体の製造方法及びその中間体
CN114702427A (zh) * 2019-10-25 2022-07-05 年衍药业(珠海)有限公司 吡咯酰胺类化合物及其用途
CA3213094A1 (en) * 2021-03-30 2022-10-06 Qiao ZONG Crystalline form of pyrrole amide compound, preparation method therefor and use thereof
CN115784961A (zh) * 2021-09-10 2023-03-14 上海鼎雅药物化学科技有限公司 埃沙西林酮及其中间体的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041596T2 (hu) * 2004-07-30 2019-05-28 Exelixis Inc Pirrol származékok mint gyógyászati szerek
DK2133330T3 (da) * 2007-04-09 2014-03-31 Daiichi Sankyo Co Ltd Atropisomer af pyrrolderivat

Also Published As

Publication number Publication date
TWI547479B (zh) 2016-09-01
TW201028377A (en) 2010-08-01
AU2009302371B2 (en) 2015-02-12
CA2736923A1 (en) 2010-04-15
JP5767586B2 (ja) 2015-08-19
BRPI0920459A2 (pt) 2020-08-11
TW201627283A (zh) 2016-08-01
JP2014196365A (ja) 2014-10-16
WO2010042622A1 (en) 2010-04-15
CN102186817B (zh) 2017-05-17
EP2349997B1 (en) 2015-08-12
ES2547697T3 (es) 2015-10-08
IL212170A (en) 2016-03-31
AU2009302371A1 (en) 2010-04-15
KR20110091663A (ko) 2011-08-12
TWI593674B (zh) 2017-08-01
KR101643285B1 (ko) 2016-07-29
JP2012505225A (ja) 2012-03-01
BRPI0920459B1 (pt) 2021-12-14
CA2736923C (en) 2016-11-22
JP6121952B2 (ja) 2017-04-26
CN102186817A (zh) 2011-09-14
EP2349997A1 (en) 2011-08-03
US8487117B2 (en) 2013-07-16
US20110263673A1 (en) 2011-10-27
IL212170A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
HRP20150477T8 (hr) Postupci dobivanja derivata kinazolona
AP2011005943A0 (en) Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.
ME02455B (me) Derivati indazola supstituisanog sa benzodioksinilom
IL210462A0 (en) Pyrimidine compounds, compositions and methods of use
IL207100A0 (en) 2-amino-quinoline derivatives useful as inhibitors of b-secretase (bace)
HK1148283A1 (zh) 雜環衍生物
IL210176A0 (en) Substituted pyrimidone derivatives
ZA201006104B (en) Substituted xanthine derivatives
ZA201102123B (en) Substituted triazolo-pyridazine derivatives
PT2133330E (pt) Atropisómero de derivado de pirrole
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
EP2242493A4 (en) Gefitinib DERIVATIVES
PL2328545T3 (pl) Zastosowanie glukozyloglicerolu
IL218696A0 (en) 2-oxo-1- pyrrolidinyl imidazothiadiazole derivatives
EP2370414A4 (en) PREPARATION OF CAPECITABINE
GB0713564D0 (en) New medical use of triazine derivatives
ZA201006854B (en) Conversion of tryptophan into b-carboline derivatives
HK1155163A1 (zh) 羥基烷基 吡咯衍生物的阻轉異構體
GB0921210D0 (en) Novel heterocyclic derivatives
ZA201105219B (en) (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
ZA200809112B (en) N-oxides of pyridylmethylpiperazine and -piperidine derivatives
GB0703514D0 (en) Use of riboflavin
GB0821710D0 (en) Derivatives of dihydroindolone
IL194758A0 (en) N-oxides of pyridylmethylpipertazine and-piperidine derivatives
GB0717955D0 (en) Preparation of modified nucleosides